secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2023-03-10T23:59:59+00:00
Accession:  0001493152-23-007176
Event type: dividend
Sentiment:  neutral
Materiality: 0.80
Item codes: 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine Amends Bylaws and Declares Series B Preferred Stock Dividend for Reverse Stock Split Vote
--------------------------------------------------------------------------------

- Bylaw Amendment adopted March 7, 2023, reducing stockholder quorum from a majority to one-third of outstanding shares.
- Board declared dividend of 1/1000th share of Series B Preferred Stock per common share, record date March 24, 2023.
- Each Series B Preferred share carries 1,000,000 votes, voting solely on reverse stock split and adjournment proposals.
- Series B Preferred is non-transferable except with common stock; shares are subject to automatic redemption before or after the reverse stock split vote.
- Press release issued March 10, 2023, announcing the pro rata distribution of Series B Preferred Stock to common stockholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315223007176/0001493152-23-007176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315223007176/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-007176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer